Stay updated with breaking news from Multiple Sclerosis Functional Composite. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Long-term CNM-Au8 treatment demonstrated significant and clinically meaningful improvement of vision as measured by low contrast letter acuity (LC...
Ad Scientiam Launches International Study to Assess Disability Progression ...
Ad Scientiam Launches International Study to Assess Disability Progression in Multiple Sclerosis With MSCopilot PARIS, FRANCE / ACCESSWIRE / September 12, 2023 / Ad Scientiam, a global leader in...
Supplements with tauroursodeoxycholic acid (TUDCA) were generally well tolerated among people with progressive forms of MS in a small trial.
The upcoming global Phase 3 clinical trial will test CNM-Au8's effect on MS disease progression that occurs independently of relapse activity.